PMID- 15613981
OWN - NLM
STAT- MEDLINE
DCOM- 20050615
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 45
IP  - 1
DP  - 2005 Jan
TI  - Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte 
      chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit 
      atherosclerotic balloon injury model.
PG  - 61-7
AB  - The inflammation in response to vascular injury is becoming increasingly 
      recognized as a potential contributor to restenosis. Cyclooxygenase-2 (COX-2) is 
      the inducible form of cyclooxygenase and has been shown to be involved in the 
      proinflammatory response of vascular tissue. Bilateral femoral artery lesions 
      were induced by air desiccation in New Zealand White rabbits followed by high 
      cholesterol diet feeding for 28 days. Balloon injury and stent implantation were 
      performed at the preinjured vessel segments. Immunostaining showed that uninjured 
      vessel segments stained positive only for COX-1 but not for COX-2. Injured vessel 
      segments showed, in addition to COX-1, significant positive staining for COX-2. 
      In the efficacy study, celecoxib (75 mg/kg/d) was administered orally beginning 3 
      hours before balloon injury or stent implantation on day 28 and daily for 21 
      days. Monocyte chemoattractant protein-1 (MCP-1) and matrix metalloproteinase-2 
      and -9 (MMPs) expression were quantified in arterial extracts 4 days after 
      balloon injury by Western blot and gelatin zymography. Morphometric analysis and 
      immunostaining for macrophages were performed 21 days after balloon injury. 
      Celecoxib treatment significantly decreased MCP-1 expression (P < 0.01). 
      Neointimal hyperplasia was significantly inhibited by celecoxib in both balloon 
      injury and stent models (0.49 +/- 0.20 versus 0.70 +/- 0.35 mm2 from balloon 
      injury model, P < 0.05, and 0.81 +/- 0.25 versus 1.69 +/- 0.43 mm2 from stent 
      model, P < 0.05), accompanied by reduced macrophage infiltration. We conclude 
      that celecoxib decreases the inflammatory response and intimal hyperplasia 
      following vascular injury, possibly through inhibition of MCP-1 expression, 
      implying a pivotal role of inflammation in the pathogenesis of restenosis.
FAU - Wang, Kai
AU  - Wang K
AD  - Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 
      Cleveland, Ohio 44195, USA. wangk@ccf.org
FAU - Tarakji, Khaldoun
AU  - Tarakji K
FAU - Zhou, Zhongmin
AU  - Zhou Z
FAU - Zhang, Ming
AU  - Zhang M
FAU - Forudi, Farhad
AU  - Forudi F
FAU - Zhou, Xiaorong
AU  - Zhou X
FAU - Koki, Alane T
AU  - Koki AT
FAU - Smith, Mark E
AU  - Smith ME
FAU - Keller, Bradley T
AU  - Keller BT
FAU - Topol, Eric J
AU  - Topol EJ
FAU - Lincoff, A Michael
AU  - Lincoff AM
FAU - Penn, Marc S
AU  - Penn MS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Matrix Metalloproteinase Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - EC 1.14.99.1 (Cyclooxygenase 1)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
RN  - JCX84Q7J1L (Celecoxib)
SB  - IM
MH  - Angioplasty, Balloon
MH  - Animals
MH  - Arteriosclerosis/etiology/*metabolism/*pathology
MH  - Celecoxib
MH  - Chemokine CCL2/*antagonists & inhibitors/biosynthesis
MH  - Cyclooxygenase 1
MH  - Cyclooxygenase 2
MH  - Cyclooxygenase 2 Inhibitors
MH  - Cyclooxygenase Inhibitors/pharmacokinetics/*pharmacology
MH  - Female
MH  - Hyperplasia
MH  - Iliac Artery/drug effects/pathology
MH  - Male
MH  - Matrix Metalloproteinase 2/biosynthesis
MH  - Matrix Metalloproteinase 9/biosynthesis
MH  - Matrix Metalloproteinase Inhibitors
MH  - Prostaglandin-Endoperoxide Synthases/*biosynthesis
MH  - Pyrazoles/pharmacokinetics/*pharmacology
MH  - Rabbits
MH  - Stents
MH  - Sulfonamides/pharmacokinetics/*pharmacology
MH  - Tunica Intima/*drug effects/pathology
EDAT- 2004/12/23 09:00
MHDA- 2005/06/16 09:00
CRDT- 2004/12/23 09:00
PHST- 2004/12/23 09:00 [pubmed]
PHST- 2005/06/16 09:00 [medline]
PHST- 2004/12/23 09:00 [entrez]
AID - 00005344-200501000-00011 [pii]
AID - 10.1097/00005344-200501000-00011 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2005 Jan;45(1):61-7. doi: 
      10.1097/00005344-200501000-00011.